SCYNEXIS has a long-standing commitment to the discovery of anti-parasitic drugs for Human Health (Neglected Tropical Diseases), Animal Health and Public Health. To achieve this SCYNEXIS has developed a state-of-the art-platform to allow for the assessment of chemical libraries against over 30 parasite species relevant to global health. SCYNEXIS has a proven track record of success in the identification of chemical series with anti-parasitic properties that are currently being evaluated in animal and human clinical studies.
SCYNEXIS Integrated Parasitology Platform
The SCYNEXIS Integrated Parasitology platform allows for the evaluation of chemical libraries against a broad range of parasite species thus allowing for the efficient alignment of a chemical series to the appropriate therapeutic area. SCYNEXIS expertise in anti-parasitic drug discovery covers a broad range of important indications. SCYNEXIS has developed a variety of ex vivo and in vitro assays that allow for the evaluation of compounds directly against parasites of interest. Screening paradigms have been implemented that progress compounds from ex vivo and in vitro assays into in vivo efficacy and safety models. Each lead optimization process is tailored to the Target Product Profile (TPP) for the appropriate disease indication. SCYNEXIS integrated discovery teams, consisting of biology, chemistry and DMPK scientists work together to progress lead compound series through pre-clinical into clinical candidate nomination stage followed by partnership-based clinical development and delivery to patients.
Partnering with SCYNEXIS
The SCYNEXIS discovery team works with your scientists to design a program to meet your project goals. SCYNEXIS can design programs focused on a specific subset of parasites or allow for a broader evaluation of your compound collection. The format for compound submission to SCYNEXIS screening program is flexible and chemical structures are not required for testing. We maintain confidentiality and will work with you to develop your unique IP portfolio.